

# Blastomycosis- Market Insights, Epidemiology and Market Forecast 2028

https://marketpublishers.com/r/B563B36B2BCEN.html

Date: June 2019 Pages: 101 Price: US\$ 5,980.00 (Single User License) ID: B563B36B2BCEN

# Abstracts

**REPORT SUMMARY** 

'Blastomycosis- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering? United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan

Study Period: 2016-2028

# Blastomycosis Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Blastomycosisin the US, Europe, and Japan are also provided in the report.

Blastomycosis Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies,



survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

#### Blastomycosis Product Profiles & Analysis

This part of the Blastomycosis report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

# Blastomycosis Market Outlook

The Blastomycosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market at first sight.

#### Blastomycosis Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Blastomycosis Report Insights Patient Population in Blastomycosis Therapeutic Approaches in Blastomycosis Blastomycosis Pipeline Analysis Blastomycosis Market Size and Trends



Blastomycosis Market Opportunities Impact of upcoming Therapies in Blastomycosis

Blastomycosis Report Key Strengths 10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition

Blastomycosis Report Assessment Current Treatment Practices in Blastomycosis Unmet Needs in Blastomycosis Detailed Blastomycosis Pipeline Product Profiles Market Attractiveness Market Drivers and Barriers

**Key Benefits** 

This report will help to develop Business Strategies by understanding the trends shaping and driving the Blastomycosis market Organize sales and marketing efforts by identifying the best opportunities for Blastomycosis market To understand the future market competition in the Blastomycosis market.

**Note:** We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



# Contents

# **1 KEY INSIGHTS**

# 2 BLASTOMYCOSIS MARKET OVERVIEW AT A GLANCE

- 2.1 Market Share (%) Distribution of Blastomycosis in 2018
- 2.2 Market Share (%) Distribution of Blastomycosis in 2028

# 3 BLASTOMYCOSIS: DISEASE BACKGROUND AND OVERVIEW

- 3.1 Introduction
- 3.2 Symptoms
- 3.3 Etiology
- 3.4 Risk Factor
- 3.5 Pathophysiology
- 3.6 Diagnosis
- 3.7 Treatment

# 4 EPIDEMIOLOGY AND PATIENT POPULATION

- 4.1. Key Findings
- 4.2. Total Prevalent/ Incident Patient Population of Blastomycosis in 7MM
- 4.3. Total Prevalent Patient Population of Blastomycosis in 7MM By Countries

# 5 EPIDEMIOLOGY OF BLASTOMYCOSIS BY COUNTRIES (2016-2028)

- 5.1 United States- Epidemiology (2016-2028)
  - 5.1.1 Assumptions and Rationale
- 5.1.2 Prevalent/Incident Cases of Blastomycosis in the United States
- 5.1.3 Sub-Type Specific cases of Blastomycosis in the United States
- 5.1.4 Sex- Specific Cases of Blastomycosis in the United States
- 5.1.5 Diagnosed Cases of Blastomycosis in the United States
- 5.1.6 Treatable Cases of Blastomycosis in the United States

# 5.2 EU5 Countries

- 5.2.1 Germany
  - 5.2.1.1 Assumptions and Rationale
  - 5.2.1.2 Prevalent/Incident Cases of the of Blastomycosis in the Germany
  - 5.2.1.3 Sub-Type Specific cases of Blastomycosis in the Germany



- 5.2.1.4 Sex- Specific Cases of the Blastomycosis in the Germany
- 5.2.1.5 Diagnosed Cases of the Blastomycosis in the Germany
- 5.2.1.6 Treatable Cases of the Blastomycosis
- 5.2.2 France
  - 5.2.2.1 Assumptions and Rationale
  - 5.2.2.2 Prevalent/Incident Cases of the of Blastomycosis in the France
- 5.2.2.3 Sub-Type Specific cases of Blastomycosis in the France
- 5.2.2.4 Sex- Specific Cases of the Blastomycosis in the France
- 5.2.2.5 Diagnosed Cases of the Blastomycosis in the France
- 5.2.2.6 Treatable Cases of the Blastomycosis
- 5.2.3 Italy
  - 5.2.3.1 Assumptions and Rationale
  - 5.2.3.2 Prevalent/Incident Cases of the of Blastomycosis in the Italy
- 5.2.3.3 Sub-Type Specific cases of Blastomycosis in the Italy
- 5.2.3.4 Sex- Specific Cases of the Blastomycosis in the Italy
- 5.2.3.5 Diagnosed Cases of the Blastomycosis in the Italy
- 5.2.3.6 Treatable Cases of the Blastomycosis
- 5.2.4 Spain
  - 5.2.4.1 Assumptions and Rationale
  - 5.2.4.2 Prevalent/Incident Cases of the of Blastomycosis in the Spain
  - 5.2.4.3 Sub-Type Specific cases of Blastomycosis in the Spain
- 5.2.4.4 Sex- Specific Cases of the Blastomycosis in the Spain
- 5.2.4.5 Diagnosed Cases of the Blastomycosis in the Spain
- 5.2.4.6 Treatable Cases of the Blastomycosis
- 5.2.5 United Kingdom
- 5.2.5.1 Assumptions and Rationale
- 5.2.5.2 Prevalent/Incident Cases of the of Blastomycosis in the United Kingdom
- 5.2.5.3 Sub-Type Specific cases of Blastomycosis in the United Kingdom
- 5.2.5.4 Sex- Specific Cases of the Blastomycosis in the United Kingdom
- 5.2.5.5 Diagnosed Cases of the Blastomycosis in the United Kingdom
- 5.2.5.6 Treatable Cases of the Blastomycosis
- 5.3 Japan
  - 5.3.1 Assumptions and Rationale
  - 5.3.2 Prevalent/Incident Cases of the of Blastomycosis in the Japan
  - 5.3.3 Sub-Type Specific cases of Blastomycosis in the Japan
  - 5.3.4 Sex- Specific Cases of the Blastomycosis in the Japan
  - 5.3.5 Diagnosed Cases of the Blastomycosis in the Japan
  - 5.3.6 Treatable Cases of the Blastomycosis



#### **6 CURRENT TREATMENT & MEDICAL PRACTICES**

- 6.1 Treatment Algorithm
- 6.2 Treatment Guidelines

#### **7 UNMET NEEDS**

#### **8 MARKETED PRODUCT**

- 8.1 Drug A: Company
- 8.1.1 Drug Description
- 8.1.2 Mechanism of Action
- 8.1.3 Clinical Trials Details
- 8.1.4 Advantages & Disadvantages
- 8.1.5 Safety and Efficacy
- 8.1.6 Product Profile
- 8.2 Drug B: Company
- 8.2.1 Drug Description
- 8.2.2 Mechanism of Action
- 8.2.3 Clinical Trials Details
- 8.2.4 Advantages & Disadvantages
- 8.2.5 Safety and Efficacy
- 8.2.6 Product Profile
- 8.3 Drug C: Company
  - 8.3.1 Drug Description
  - 8.3.2 Mechanism of Action
  - 8.3.3 Clinical Trials Details
  - 8.3.4 Advantages & Disadvantages
  - 8.3.5 Safety and Efficacy
  - 8.3.6 Product Profile
- 8.4 Drug D: Company
  - 8.4.1 Drug Description
  - 8.4.2 Mechanism of Action
  - 8.4.3 Clinical Trials Details
  - 8.4.4 Advantages & Disadvantages
  - 8.4.5 Safety and Efficacy
  - 8.4.6 Product Profile
- 8.5 Drug E: Company
- 8.5.1 Drug Description



- 8.5.2 Mechanism of Action
- 8.5.3 Clinical Trials Details
- 8.5.4 Advantages & Disadvantages
- 8.5.5 Safety and Efficacy
- 8.5.6 Product Profile
- 8.6 : Company
  - 8.6.1 Drug Description
  - 8.6.2 Mechanism of Action
  - 8.6.3 Clinical Trials Details
  - 8.6.4 Advantages & Disadvantages
  - 8.6.5 Safety and Efficacy
  - 8.6.6 Product Profile
- 8.7 : Company
  - 8.7.1 Drug Description
  - 8.7.2 Mechanism of Action
  - 8.7.3 Clinical Trials Details
  - 8.7.4 Advantages & Disadvantages
  - 8.7.5 Safety and Efficacy
  - 8.7.6 Product Profile
- 8.8 : Company
  - 8.8.1 Drug Description
  - 8.8.2 Mechanism of Action
  - 8.8.3 Clinical Trials Details
  - 8.8.4 Advantages & Disadvantages
  - 8.8.5 Safety and Efficacy
  - 8.8.6 Product Profile

# **9 EMERGING DRUGS**

- 9.1 Key Cross Competition
- 9.2 Emerging company
  - 9.2.1 Emerging Drug A: Company
    - 9.2.1.1 Other Development Activities
  - 9.2.1.2 Clinical Development
  - 9.2.1.3 Clinical Trials Information
  - 9.2.1.4 Safety and Efficacy
  - 9.2.1.5 Advantages and Disadvantages
  - 9.2.1.6 Product Profile
  - 9.2.2 Emerging Drug B: Company



- 9.2.2.1 Other Development Activities
- 9.2.2.2 Clinical Development
- 9.2.2.3 Clinical Trials Information
- 9.2.2.4 Safety and Efficacy
- 9.2.2.5 Advantages and Disadvantages
- 9.2.2.6 Product Profile
- 9.2.3 Emerging Drug C: Company
  - 9.2.3.1 Other Development Activities
  - 9.2.3.2 Clinical Development
- 9.2.3.3 Clinical Trials Information
- 9.2.3.4 Safety and Efficacy
- 9.2.3.5 Advantages and Disadvantages
- 9.2.3.6 Product Profile
- 9.2.4 Emerging Drug D: Company
- 9.2.4.1 Other Development Activities
- 9.2.4.2 Clinical Development
- 9.2.4.3 Clinical Trials Information
- 9.2.4.4 Safety and Efficacy
- 9.2.4.5 Advantages and Disadvantages
- 9.2.4.6 Product Profile
- 9.2.5 Emerging Drug E: Company
  - 9.2.5.1 Other Development Activities
  - 9.2.5.2 Clinical Development
  - 9.2.5.3 Clinical Trials Information
  - 9.2.5.4 Safety and Efficacy
- 9.2.5.5 Advantages and Disadvantages
- 9.2.5.6 Product Profile

# **10 7MM MARKET ANALYSIS**

- 10.1 7MM Market Size of Blastomycosis
- 10.2 7MM Percentage Share of Drugs Marketed for Blastomycosis
- 10.3 7MM Market Sales of Blastomycosis by Products

# 11 THE UNITED STATES MARKET OUTLOOK

- 11.1 Market Size of Blastomycosis in United States
- 11.2 Percentage Share of Drugs Marketed for Blastomycosis in United States
- 11.3 Market Sales of Blastomycosis by Products in United States



11.4 Analysis of Upcoming Therapies and Impact on the Market

#### **12 EU5 COUNTRIES MARKET OUTLOOK**

- 12.1 Market Size of Blastomycosis in EU5
- 12.2 Market Size of Blastomycosis in Germany
- 12.2.1 Market Size of Blastomycosis in Germany
- 12.2.2 Percentage Share of Drugs Marketed for Blastomycosis in Germany
- 12.2.3 Market Sales of Blastomycosis by Products in Germany
- 12.2.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.3 Market Size of Blastomycosis in France
- 12.3.1 Market Size of Blastomycosis in France
- 12.3.2 Percentage Share of Drugs Marketed for Blastomycosis in France
- 12.3.3 Market Sales of Blastomycosis by Products in France
- 12.3.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.4 Market Size of Blastomycosis in Italy
- 12.4.1 Market Size of Blastomycosis in Italy
- 12.4.2 Percentage Share of Drugs Marketed for Blastomycosis in Italy
- 12.4.3 Market Sales of Blastomycosis by Products in Italy
- 12.4.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.5 Market Size of Blastomycosis in Spain
- 12.5.1 Market Size of Blastomycosis in Spain
- 12.5.2 Percentage Share of Drugs Marketed for Blastomycosis in Spain
- 12.5.3 Market Sales of Blastomycosis by Products in Spain
- 12.5.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.6 Market Size of Blastomycosis in United Kingdom
  - 12.6.1 Market Size of Blastomycosis in United Kingdom
  - 12.6.2 Percentage Share of Drugs Marketed for Blastomycosis in United Kingdom
  - 12.6.3 Market Sales of Blastomycosis by Products in United Kingdom
- 12.6.4 Analysis of Upcoming Therapies and Impact on the Market

# **13 THE JAPAN MARKET OUTLOOK**

- 13.1 Market Size of Blastomycosis in Japan
- 13.2 Percentage Share of Drugs Marketed for Blastomycosis in Japan
- 13.3 Market Sales of Blastomycosis by Products in Japan
- 13.4 Analysis of Upcoming Therapies and Impact on the Market

# 14 COST ANALYSIS OF BLASTOMYCOSIS



#### **15 GENERIC COMPETITION IN BLASTOMYCOSIS MARKET**

#### **16 MARKET DRIVERS**

# **17 MARKET BARRIERS**

#### **18 REPORT METHODOLOGY**

- 18.1 Methodology/Research Approach
- 18.2 Data Source
  - 18.2.1 Secondary Sources
  - 18.2.2 Primary Sources



# I would like to order

Product name: Blastomycosis- Market Insights, Epidemiology and Market Forecast 2028 Product link: <u>https://marketpublishers.com/r/B563B36B2BCEN.html</u>

> Price: US\$ 5,980.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

# Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/B563B36B2BCEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970